Background: Platelet Transfusion are used for the treatment and prevention of bleeding in patients with decreased number and function of platelets. Platelet for transfusion can be provided by platelet concentrates, which are obtained either by PRP or buffy coat method from whole blood or by apheresis. Platelet Recovery in a patient is influenced by the transfused dose of platelets which in turn is dependent on the platelet yield. Aim of Study: In this study, our main objective is to identify the donor parameters that influence the platelet yield obtained by apheresis. Methods: This prospective study was undertaken in the Department of IHBT.140 healthy donors were selected for plateletpheresis according to guidelines laid down by Drugs and cosmetics Act over a period of one year. The plateletpheresis procedures were performed on Haemonetics MCS plus separator. Yield predicting donor variables included in the study were Age, Gender, Haemoglobin concentration, Haematocrit and Platelet count. The relationship between predonation donor variable and yield was studied using pearson correlation. Results: The Mean platelet yield was 3.19±0.48×10 11 per unit. Mean predonation platelet count of donor was 2.77± 0.46×10 5 /µl. Mean age of the Donor was 30.31±8.14. Positive Correlation was observed between platelet yield and predonation platelet count of donor(r=0.318, P value 0.0001) which is significant. No such correlation was seen between platelet yield and Haemoglobin(r=0.131, P value 0.122), Haematocrit (r=0.058, P value 0.499), Age of Donor(r=0.034, P value 0.692). Conclusion: The possibility of obtaining higher platelet yield reduces the frequency of platelet transfusion and number of donor exposures with important consequent clinical and economic advantages.

Background: Red blood cell (RBC) alloimmunization is an immune response against foreign RBC antigens; this generally occurs after sensitization due to multiple blood transfusions and pregnancies. Antibody detection plays a critical role in transfusion medicine as it can detect irregular or unexpected antibodies. This study was done to know the frequency and specificity of unexpected red cell antibodies in the multitransfused patients. Materials and Methods: This prospective study was done in the Department of Immuno-Haematology and Blood Transfusion. Antibody screening of 100 multitransfused patients with initial negative antibody screen was carried out prior to compatibility testing and followed for a period of 12 months for each transfusion. Depending on the results, patients were given corresponding antigen-negative blood units. Results: In this study, the rate of alloimmunization was 7%. Total number of samples that were positive for irregular alloantibodies were 4 of 54 cases of thalassemia, that is, 7.4%, whereas 3 of 40, that is, 7.5%, cases of solid malignancies developed alloantibodies. None of the patients of chronic kidney disease formed any alloantibody. Anti-K antibody was the most frequent antibody detected in 3 of 7, that is, 42.8% patients. Anti-E was the second most frequent antibody observed in 2 of 7, that is, 28.57%. However, anti-c and anti-M were detected in one each of 7, that is, in 14.28% each. Conclusion: It is concluded here that red cell alloimmunization should not be overlooked in multitransfused patients. To avoid the effects of alloimmunization, routine RBC antibody screening at set time intervals after transfusion should be performed.

No abstract

No abstract